-
Product Insights
NewNet Present Value Model: Scholar Rock Holding Corp’s Apitegromab
Empower your strategies with our Net Present Value Model: Scholar Rock Holding Corp's Apitegromab report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewNet Present Value Model: Scholar Rock Holding Corp’s Linavonkibart
Empower your strategies with our Net Present Value Model: Scholar Rock Holding Corp's Linavonkibart report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewBurning Rock Biotech Ltd Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Burning Rock Biotech Ltd Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Burning Rock Biotech Ltd (BRB) is a biotechnology company. It is involved in providing individualized cancer treatment guidance for the patients. The company offers core products such as OncoCompass IO, OncoScreen IO, OncoCompass Target, OncoScreen ParpMatch, Lung Core, Colon Core, Prostate Core, Onco Screen Risk, Lung Core, Colon Core, Prostate Core, Breast Core, Thyro Core, Lymph Plasma and...
-
Innovation Ranking
Innovation Ranking – Scholar Rock Holding Corp
Scholar Rock Holding Corp (Scholar Rock) is a clinical-stage biopharmaceutical company that develops novel medicines for the treatment of severe diseases in which signaling by protein growth factors plays a fundamental role. The company’s pipeline products comprise SRK-015, an inhibitor for the treatment of spinal muscular atrophy (SMA). It also develops inhibitors of latent TGFβ1 for the treatment of immune oncology and fibrosis. Scholar Rock serves in the therapeutic areas of neuromuscular disorders, fibrosis, cancer and also anemia. The company...
-
Sector Analysis
NewTravel and Tourism – Hotels – Sport Sector Sponsorship Landscape, Market Insights, Biggest Deals, Brand Analysis and Case Studies
This report provides an overview of the hotels sector, globally. It explores all the main active brands in the sector as well as details the movement in the sector over the last few years in the sports sponsorship industry. Multi-Sport Games dominates the spend in the hotels sector for 2024. Most of Multi-Sport Games deal value comes from AccorHotels partnership with Paris 2024, earth an estimated $105 million annually. American Football ranks second for the hotels sectors sports sponsorship spend,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vyznova in Corneal Edema
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vyznova in Corneal Edema report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vyznova in Corneal Edema Drug Details: Vyznova a human corneal endothelial...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Metastatic Hepatocellular Carcinoma (HCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Metastatic Hepatocellular Carcinoma (HCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Metastatic Hepatocellular Carcinoma (HCC) Drug Details: AFM-24I...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: AFM-24I...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Ovarian Cancer Drug Details: AFM-24I is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AFM-24I in Cervical Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AFM-24I in Cervical Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AFM-24I in Cervical Cancer Drug Details: AFM-24I is under development for...